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Abstract
Background: Infection with Helicobacter pylori is associated with severe digestive diseases including chronic
gastritis, peptic ulcer disease, and gastric cancer. Successful eradication of this common gastric pathogen in
individual patients is known to prevent the occurrence of peptic ulcer disease and gastric cancer.
Discussion: With half of the world’s population being infected with H, pylori and only few antibiotics result in an
effective eradication, a successful antibiotic driven worldwide eradication program seems unlikely. In addition,
H. pylori eradication is not always beneficial as it has been described that eradication can be associated with
an increased frequency of other disorders such as pediatric asthma, inflammatory bowel diseases and Barrett’s
Esophagus. We have to accept that eradication of this infection is a two-edged sword that is both useful and
harmful and we should therefore focus our H. pylori eradication policy toward selectively identify and destroy
only the virulent strains.
Conclusion: In order to still be able to effectively treat H. pylori infections in the future we need an alternative
diagnostic/treatment algorithm. This would involve a shift towards more precise and enhanced disease predicting
diagnosis that tries to identify patients with chance of developing severe diseases such as gastric cancer, rather than
the current regime that is geared towards find and destroy all H. pylori.
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Background
With >50 % of the world’s population colonized by
Helicobacter pylori it is one of the most prevalent
human pathogens [1]. Infection with H. pylori is asso-
ciated with chronic gastritis, duodenal ulcer, gastric
cancer and even gastric adenocarcinoma [2]. Infection
is usually acquired in childhood via person-to-person
fecal-oral, oral-oral, or gastro-oral transmission being
the most likely route of infection [3]. When ingested
the bacterium colonizes the mucous layer covering
the epithelial cells of the stomach and this induces an
immune response that in spite of its vigor is unable
to eliminate the bacterium [4]. The chronic infection
that results from this vigorous but typically inad-
equate immune response induces gastric damage that
is associated with digestive disorders ranging from
chronic gastritis to peptic ulcer disease, and gastric
cancer, but in most cases H. pylori infected patients
remain asymptomatic for a long time [5]. In contrast
to many other infectious agents the final outcome of
a H. pylori infection is different for each infection
and is dependent on both host and bacterial factors
[1]. The large genetic variation observed among clin-
ical strains of H. pylori is thought to be an important
determinant in the specific local establishment of this
colonization and determines in large part the develop-
ment of the potential disorders that result from the
infection [6]. The remarkable genetic and phenotypic
diversity observed in H. pylori is thought to be driven
by the need to adapt to the harsh and patient specific
conditions of the gastric environment that often result
in the genesis of various subpopulations (quasispecies)
within single patients [7]. This results in each infected
person potentially carrying genetically unique micro-
organisms existing only in that particular patient [7, 8].
Depending on the presence of specific H. pylori viru-
lence factors such as dupA, cagA, vacA and homB
the bacterium usually colonizes the antral mucosa of
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human stomach [8]. Once this primary colonization is
established it induces an inflammation that remains
largely asymptomatic (Fig. 1) [9, 10]. In fact, an acute in-
fection and subsequent gastritis precede the more severe
digestive disorders such as gastric bleeding, peptic ulcers,
and gastric cancer known to be associated with H. pylori
infection (Fig. 1) [10]. While a long list of antibiotics has
been tested for their effectiveness on H. pylori only a
handful of them can be used for effective H. pylori eradi-
cation. Treatment options are further reduced as effective
therapeutic regimen requires a combination of two or
three antibiotics and a gastric acid suppressive drug [11].
Finally, in H. pylori antibiotic resistance to these drugs
rapidly emerges as the resistance against all these drugs
does not require the introduction of specific genes, but in
all cases is based on a single point mutation in an existing
housekeeping gene thus and obviously this further reduces
a broad clinical efficacy significantly [4, 12, 13]. In parallel
with emergence of multidrug resistant bacteria in other
bacterial species, we need to accept that there is a rapid
and ongoing reduction of the effective lifespan of antibi-
otics for clinical applications [14]. This has resulted in a
situation where the big companies stopped or reduced
their efforts to develop new antibiotics. While vaccination
may be a practical approach for many pathogens, in the
case of H. pylori vaccines do not seem to represent a
viable option as sterilizing immunity is not considered an
endpoint for now [15, 16]. As currently vaccines and pre/
probiotics do not offer realistic H. pylori eradication strat-
egies antibiotic treatment is currently the only available
option to effectively reduce the gastrointestinal disorders
resulting from H. pylori infection [17–19]. For now the
further increase of antimicrobial resistance in H. pylori is
being endangered by clinicians that frequently prescribe
clarithromycin for patients suffering from upper respira-
tory diseases. Especially in developing countries many of
these respiratory disease patients will also be colonized
with H. pylori, but as here H. pylori infection is still in its
early stage it will probably not have resulted in any signifi-
cant disease symptoms and thus go unnoticed. Treating
these patients with antibiotics with what should be con-
sidered for H. pylori as low dose, relative short period, and
in the absence of an acid suppressive agent will not eradi-
cate the H. pylori colonization but instead is very likely to
promote the generation of resistant H. pylori. Hence we
would need to create the awareness amongst clinicians
that they might need to save the few remaining effective
H. pylori drugs such as clarithromycin and amoxicillin
and not use them freely for the treatment of common
respiratory and urinary tract infections because of the
consequences this may have on future H. pylori treatment
of their patients. Or in minimum test for the absence of
H. pylori in these patients and refrain from the use of
effective H. pylori drugs when a patient is positive.
Discussion
While many diagnostic tests for detecting H. pylori are
expensive and/or time consuming, our above suggestion
to apply molecular detection will probably not get much
support. Especially since currently when treating H. pylori
infections more and more eradication therapies are being
prescribed without testing for antimicrobial sensitivity in
Fig. 1 Stopping the Helicobacter pylori induced disease cascade. Depending on the host and bacterial characteristics the initial colonization will
result in gastritis and this will either result in clinical symptoms (symptomatic patient) where screening for the presence of Helicobacter and its
resistance needs to be performed in order to allow for rational treatment. If the infection does not result in clinical symptoms (asymptomatic
patient) it may still be advisable to use a single non-invasive fecal antigen screen at age 40 or so (when usually symptoms have not yet developed) to
test for the presence of Helicobacter. When this test is positive fecal DNA test detecting Helicobacter specific virulence factors to predict infection
with a virulent strain, and/or a noninvasive serologic follow-up screen to establish the degree of atrophy is advisable. If either of these tests predict
there is a high risk for the development of gastric cancer eradication is advisable. Elimination of strains that contain virulence markers associated with
an increased risk for disease development (regardless of what pathogenicity - if any it is causing in its current host) will l reduce the spread of virulent
strains and thereby force the population of circulating Helicobacter isolates into less pathogenic Helicobacters, irrespective of the contribution of host
genetics and environmental factors
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order to save costs [17]. Effectively this means that often a
combination therapy is prescribed without propper sensi-
tivity testing. Due to increased resistance rates this may in
fact effectively boil down to prescribing monotherapy. We
know that in those cases treatment will not only be less
effective, but in fact favors the generation of resistance to
the one drug that was effective. While currently invasive
procedures are still required in order to obtain material
for culture and antimicrobial resistance determination,
there is a now molecular method being developed that
may allow for fecal matter based PCR testing for resist-
ance against many of the commonly used H. pylori drugs
[20, 21]. It will be relatively easy to also include a selection
of H. pylori virulence markers in these tests, facilitating
screening algorithm that would allow discriminating the
good H. pylori from the bad. This would give rise to the
screening and eradication scheme outlined in Fig. 1, where
in principle only symptomatic patients would be treated
after testing for virulence and resistance. Only anti-H.
pylori therapies that can achieve eradication rate ≥90 %
are considered effective, but increasing resistance ham-
pers the efficacy of prescribed regimens [12, 21, 22]. Up
to now we have taught clinicians to eradicate all cases
of H. pylori infections as they would with any other
pathogenic bacterial infection [23, 24]. However in the
light of our current knowledge where only a minority
of H. pylori infections will cause clinical symptoms
screening for H. pylori and subsequent eradication may
no longer be the best approach. For one, recent studies
showed that asthma and other diseases can appear in
the absence of H. pylori, an interesting phenomenon
which complicates links between H. pylori infection
and human disease [25, 26]. However we should consider
occurrence of gastric cancer while it can be reduced in
H. pylori infected patients through the elimination of
H. pylori (either by antibiotic therapy or vaccine) [27, 28].
Current findings are indicate an association between H.
pylori free individuals and certain immune malfunctional
diseases including allergy and asthma [26, 29], inflamma-
tory bowel diseases (IBS) [30, 31] and Barrett’s Esophagus
(BE) [32] in Helicobacter free patients. One has to be
aware however that this protective link between H. pylori
infections and immune related disorders is not always
observed and thus disputed by some authors [33]. While
infection with H. pylori will result in gastritis subsequently
we should be aware that only very few infected patients,
even when left untreated will actually develop gastric can-
cer. Basically, an Operative Link for Gastritis Assessment
(OLGA)-staging system has been designed to simplify
evaluation of gastric atrophy [34]. This staging system was
an updated version of Sydney system, thus, the staging
system can then rank the histologic phenotypes of gastritis
with a progressively increasing gastric cancer risk [35].
Moreover, new challenge can be to develop different
algorithms that would predict people with high risk of
developing gastric cancer using the pathotype of the
infecting strain of H. pylori. In this proposed algorithm,
only virulent H. pylori strains should be targeted/elimi-
nated, thus allowing non-virulent strains to remain in
place and so that they can exert their beneficial effects.
With Next Generation Sequencing (NGS) techniques
slowly becoming a routine technique in human diag-
nostic laboratories and its prices and turn-around times
rapidly falling finding and destroying only virulent H.
pylori strains may soon become a viable option. The
classical perception that all infections should be treated
as potentially disease causing has promoted that clini-
cians were eager to eliminate H. pylori infections and
that is why they used (or in our view perhaps massively
overused) antibiotics to eradicate this infection.
Perhaps for the control of future symptoms in the
currently asymptomatic H. pylori patients we should
introduce a population based screen for the presence of
H. pylori at age 50 using a non-invasive test like the fecal
antigen test or urease breath tests to establish the pres-
ence of a H. pylori infection (Fig. 1) [36]. For those posi-
tive follow-up screening with either non-invasive
molecular test that establishes the virulence of the in-
fecting strain (see above), and/or a serologic tests that
would predict the status of the atrophy [37]. If these
tests would predict an increased risk of future disease
development, treatment would then be indicated, and
one would proceed as outlined above for the symptom-
atic patient. The problem of H. pylori antibiotic resist-
ance is real and as a result, we are now confronted with
a new generation of multi drug resistant H. pylori
strains, for which suitable treatment options no longer
exist.
Conclusion
Thus we may need to revise the available guidelines to
include the option where the best possible treatment of
an infection may no longer be geared towards blindly
eradicating all infected patients (search and destroy)
but be directed towards a selective eradication strategy
(find and destroy only virulent strains). However this
requires the implementation of effective strategies to
identify virulent strains as well as awareness amongst
physicians that treatment of all individual patients may
severely limit the treatment options for our future
patients.
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